Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

RoslinCT and BOOST Pharma Form Strategic Manufacturing Partnership to Advance Cell Therapy for Osteogenesis Imperfecta

approved therapies. OI is characterized by fragile bones and reduced bone mass resulting in bones that break easily, loose joints, and weakened teeth. In severe cases, those with OI may experience hundreds of fractures in a lifetime. In addition,...

Orum Therapeutics Names Chad May Chief Scientific Officer to Advance Degrader-Antibody Conjugate Programs

play a central role in shaping the next stage of Orum’s technology innovation and pipeline growth. “The opportunity to join Orum at this stage of growth is incredibly compelling,” said Dr. May. “The Company’s Dual-Precision Targeted Protein...

GMA with MOVIVA®: Setting New Standards in Endoscopic Bariatric Treatment.

Felstead, Chief Commercial Officer at Erbe Elektromedizin. Register for the free webinar "Advancing bariatric endoscopy" Join Prof. Ivo Boskoski, MD, Christopher McGowan, MD and Abdullah AlMousa, MD on 11 December for a live online session on the...

Eisai Completes FDA Submission for LEQEMBI® IQLIK™ Subcutaneous Starting Dose.

therapy. About the Collaboration between Eisai and Biogen for AD Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory...

New long-term data confirms TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to block joint damage in active psoriatic arthritis

of structural damage at 48 weeks. At Week 24, TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo with results consistent for patients with active PsA receiving TREMFYA® every four weeks...

Odyssey Therapeutics Welcomes Dennis Dean, Ph.D., as EVP, Non-Clinical Development

scientifically rigorous, regulatory compliant, and strategically aligned with the company’s advancing portfolio. “Dennis joins Odyssey at a pivotal moment, as our lead programs advance toward later stages of development,” said Gary D. Glick, Ph.D.,...

Phase 2 Data of GC Biopharma's Recombinant Anthrax Vaccine, BARYTHRAX, Demonstrates Safety and Immunogenicity, Published in 'Vaccine

have been published in the international journal Vaccine. BARYTHRAX is the world's first recombinant anthrax vaccine, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA). This randomized, double-blind,...

Samsung Epis Holdings, Newly Established, to Drive Growth for Samsung Bioepis and Its New Subsidiary

on transforming highly scalable core technologies into platforms and discovering diverse new drug candidates, including joint development with global pharmaceutical companies. About Samsung Bioepis Co., Ltd. Samsung Bioepis will continue to focus...

During FII Week in Riyadh, Rubedo Life Sciences and SVAX announce a strategic partnership

by partnering with one of the leading pillars of the Saudi Vision 2030 National Biotech Strategy. We were honored to be joined in the signing ceremony by our new partner, Prof. Mazen Hassanain, Managing Director and CEO of SVAX, and Hevolution...

To drive global expansion of digital chemistry and discovery, Chemify raises over $50 million in an oversubscribed Series B round

In conjunction with the financing, both Ansuman Satpathy of Wing Venture Capital and Aiden Aceves of Insight Partners have joined Chemify’s Board of Directors. Founded in 2022 as a spin-out from the University of Glasgow, Chemify is reinventing...

FDA Approves ZOLL’s Zenix Monitor/Defibrillator, Elevating Asahi Kasei’s Critical Care Solutions

Healthcare sector, driving a fivefold increase in net sales and a sevenfold rise in operating income since the company joined the Asahi Kasei Group in 2012. In its medium-term management plan, Asahi Kasei has indicated it will capitalize on this...

Pharmaceutical Leader Nia Tatsis, Ph.D., Appointed to Odyssey Therapeutics’ Board of Directors

Dr. Tatsis has extensive senior-level leadership experience in global biopharmaceuticals companies. In 2017, Dr. Tatsis joined Vertex Pharmaceuticals and is responsible for managing all aspects of global regulatory affairs and quality assurance....

Leqembi® has received approval for intravenous maintenance treatment in China

has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region. About lecanemab (Leqembi®: Lecanemab is the result of a strategic research alliance...

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada. SCLC is aggressive...

Eisai submitted a rolling sBLA to the U.S. FDA for LEQEMBI® IQLIK™ as a subcutaneous starting dose to treat early Alzheimer’s, under Fast Track status

mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation. IRRs can occur during or after the...

Izalontamab Brengitecan Receives FDA Breakthrough Therapy Designation for Advanced EGFR-Mutated NSCLC

factor receptor 3 (EGFRxHER3) with a topoisomerase 1 inhibitor payload. Iza-bren is being developed by Biokin in China and jointly developed by SystImmune and Bristol Myers Squibb under a collaboration and exclusive license agreement in territories...

Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model: Tinnitus Research

were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no...

Innovent Announces Approval from China's NMPA for Mazdutide, the First Dual GCG/GLP-1 Receptor Agonist, for Chronic Weight Management

a range of diseases including diabetes, fatty liver disease, cardiovascular and cerebrovascular diseases, kidney disease, joint disorders, sleep-disordered breathing, and cancer. China has the world's largest population of individuals with...

Alafair Biosciences Announces Enrollment of First Patient in Multi-Center Study Testing VersaWrap® Tendon Protector for Achilles Repair

of time and we're now excited to take the next step and formally quantify these results." Tendons play a vital role in joint movement by connecting muscle to bone and by transmitting force. However, exposure to repetitive use, weight-bearing...

Space Cargo Unlimited and Exobiosphere Partner for High-Throughput Space Biotech

Cargo Unlimited today announced the signing of a Memorandum of Understanding (MoU) during the Paris Air Show to launch joint space missions focused on high-throughput biotechnology research. High-throughput screening (HTS) is a drug discovery...

Results 41 - 60 of 129